WO2018130063A1 - (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 - Google Patents

(r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2018130063A1
WO2018130063A1 PCT/CN2017/118180 CN2017118180W WO2018130063A1 WO 2018130063 A1 WO2018130063 A1 WO 2018130063A1 CN 2017118180 W CN2017118180 W CN 2017118180W WO 2018130063 A1 WO2018130063 A1 WO 2018130063A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
oxo
pyrrolidineacetamide
crystal
crystal form
Prior art date
Application number
PCT/CN2017/118180
Other languages
English (en)
French (fr)
Inventor
叶雷
Original Assignee
重庆润泽医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆润泽医药有限公司 filed Critical 重庆润泽医药有限公司
Priority to KR1020197019929A priority Critical patent/KR20190095346A/ko
Priority to US16/476,477 priority patent/US10961192B2/en
Priority to EP17891064.2A priority patent/EP3569590A4/en
Priority to JP2019535846A priority patent/JP2020504124A/ja
Publication of WO2018130063A1 publication Critical patent/WO2018130063A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, in particular to a crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, and a preparation method thereof And use.
  • (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide (CAS No. 68252-28-8), which is the right-handedness of the stimulant 4-hydroxy-2-oxo-1-pyrrolidone acetamide body.
  • the latest research shows that the compound has special biological activity in the fields of sedation, anti-epilepsy, etc., and its toxicity is low, and the drug safety range is large, which is expected to become an alternative to the existing highly toxic anti-epileptic drugs.
  • the specific structure of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide is as follows:
  • an object of the present invention is to provide a crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide.
  • the complete characteristics of the present invention are as follows, but for convenience, the crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide provided is referred to as "(R)-4-hydroxy- 2-oxo-1-pyrrolidine acetamide crystal form I”.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I has a relative peak intensity at a diffraction angle 2 ⁇ of 17.344 ⁇ 0.2° of 100%; and a diffraction angle of 2 ⁇ of 16.465 ⁇ 0.2°.
  • the relative peak intensity is greater than 90% and less than 100%; the relative peak intensity at the diffraction angle 2 ⁇ is 12.423 ⁇ 0.2°, 21.889 ⁇ 0.2°, and 25.054 ⁇ 0.2° is not less than 70%.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a diffraction angle 2 ⁇ of 12.423 ⁇ 0.2°, 16.285 ⁇ 0.2°, 16.465 ⁇ 0.2°, 17.344 ⁇ 0.2°. There are diffraction peaks at 20.707 ⁇ 0.2°, 21.889 ⁇ 0.2°, 25.054 ⁇ 0.2°, and 35.138 ⁇ 0.2°.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a diffraction angle 2 ⁇ of 12.423 ⁇ 0.2°, 14.928 ⁇ 0.2°, 16.285 ⁇ 0.2°, 16.465 ⁇ 0.2. °, 17.344 ⁇ 0.2°, 19.198 ⁇ 0.2°, 20.459 ⁇ 0.2°, 20.707 ⁇ 0.2°, 21.548 ⁇ 0.2°, 21.889 ⁇ 0.2°, 23.203 ⁇ 0.2°, 25.054 ⁇ 0.2°, 26.117 ⁇ 0.2°, 29.913 ⁇ 0.2 There are diffraction peaks at °, 30.49 ⁇ 0.2°, 35.138 ⁇ 0.2°, 37.569 ⁇ 0.2°, and 37.972 ⁇ 0.2°. Specifically, the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a powder diffraction pattern as shown in FIG.
  • the present invention (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I has the following d Value and relative intensity percentage I (%) value expressed by -X-ray powder diffraction data,
  • the unit cell of the (R)-4-hydroxy-2-oxo-1-pyrrolidinylacetamide crystal form I of the invention is Orthorhombic (orthogonal crystal system), Specifically, the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a crystal structure diagram as described in FIG.
  • the peak temperature of the melting point of the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention is 133.1 ⁇ 2 °C.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a differential scanning calorimetry (DSC) pattern as shown in FIG.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a diffraction angle 2 ⁇ of 12.423 ⁇ 0.2°, 14.928 ⁇ 0.2°, 16.285 ⁇ 0.2°, 16.465 ⁇ 0.2°, 17.344 ⁇ 0.2°, 19.198 ⁇ 0.2°, 20.459 ⁇ 0.2°, 20.707 ⁇ 0.2°, 21.548 ⁇ 0.2°, 21.889 ⁇ 0.2°, 23.203 ⁇ 0.2°, 25.054 ⁇ 0.2°, 26.117 ⁇ 0.2°, 29.913 ⁇ 0.2°, There are diffraction peaks at 30.49 ⁇ 0.2°, 35.138 ⁇ 0.2°, 37.569 ⁇ 0.2°, and 37.972 ⁇ 0.2°; the endothermic transition temperature is 133.1 ⁇ 2°C.
  • the infrared spectrum produced by the crystal form I of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the present invention shows an absorption peak at the following wave number:
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a diffraction angle 2 ⁇ of 12.423 ⁇ 0.2°, 14.928 ⁇ 0.2°, 16.285 ⁇ 0.2°, 16.465 ⁇ 0.2°, 17.344 ⁇ 0.2°, 19.198 ⁇ 0.2°, 20.459 ⁇ 0.2°, 20.707 ⁇ 0.2°, 21.548 ⁇ 0.2°, 21.889 ⁇ 0.2°, 23.203 ⁇ 0.2°, 25.054 ⁇ 0.2°, 26.117 ⁇ 0.2°, 29.913 ⁇ 0.2°, There are diffraction peaks at 30.49 ⁇ 0.2°, 35.138 ⁇ 0.2°, 37.569 ⁇ 0.2°, and 37.972 ⁇ 0.2°; the infrared absorption peak is shown in the following wave numbers:
  • the infrared spectrum produced by the crystal form I of the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the present invention shows an absorption peak at the following wave number:
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidinylacetamide crystal form I of the present invention has a diffraction angle 2 ⁇ of 12.423 ⁇ 0.2°, 14.928 ⁇ 0.2°, 16.285 ⁇ 0.2°, and 16.465 ⁇ 0.2°.
  • (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide is added to isopropanol or sec-butanol, continuously stirred, heated to 30 ° C ⁇ 100 ° C, filtered to form a supersaturated solution ;
  • the invention provides the use of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I for the preparation of an anti-epileptic drug.
  • the use of the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the invention for the preparation of an antiepileptic systemic episode.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidinylacetamide crystal form I of the present invention has special pharmacological activity in stabilizing abnormal brain discharge, sedation, anti-epilepsy, etc., and its solubility in water ⁇ 100mg/mL, high bioavailability.
  • a pharmaceutical composition comprising the above (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition of the present invention comprises a therapeutically effective amount of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I and a pharmaceutically acceptable excipient; it can be administered to a patient by any acceptable route of administration.
  • compositions acceptable routes of administration include, but are not limited to, oral, rectal, vaginal, nasal, inhalation, topical (including transdermal) and parenteral administration, including tablets, powders, Granules, injections, capsules, pills, sustained release controlled release preparations, freeze-dried powder injections.
  • the present invention provides a crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide having a temperature of 12.423 ⁇ 0.2°, 16.465 ⁇ 0.2°, 17.344 ⁇ 0.2°, 21.889 ⁇ 0.2°, 25.054 at 2 ⁇ . There is a diffraction peak at ⁇ 0.2°, wherein the relative peak intensity at the diffraction angle 2 ⁇ of 17.344 ⁇ 0.2° is 100%.
  • the crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the invention can promote the synthesis of phosphorylcholine and o-acylethanolamine, promote brain metabolism, and stimulate the specific central nervous pathway through the blood-brain barrier.
  • the crystal form I of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the invention has obvious effects on the acute epileptic seizure, especially the acute episode of epilepsy; the invention (R)-4- Hydroxy-2-oxo-1-pyrrolidineacetamide Form I has a good inhibitory effect on systemic seizures, partial seizures and status epilepticus of epilepsy, and (R)-4-hydroxy-2- of the present invention
  • Oxy-1-pyrrolidine acetamide crystal form I has high bioavailability and low toxicity, and is suitable for development as an anti-epileptic drug.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form of the invention has a melting point peak temperature of 133.1 ⁇ 2° C., and has a fast dissolution rate in water, a solubility in water of ⁇ 100 mg/mL, and high bioavailability.
  • the crystal form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the invention is placed at a high temperature of 60 ° C for 5 days, and the change of the substance is small, and the stability to high temperature is good, and the invention (R)- 4-hydroxy-2-oxo-1-pyrrolidinoacetamide crystal form particles have good fluidity, can meet the liquidity requirements in the production process, and are suitable for the production of pharmaceutical preparations, storage and transportation; suitable for making various pharmaceutical compositions, A variety of preparations such as tablets, capsules, pills, sustained release controlled release preparations, lyophilized powder injections and the like can be prepared.
  • the preparation method of the invention adopts the raw material with low cost and easy availability, and the prepared (R)-4-hydroxy-2-oxo-1-pyrrolidinylacetamide crystal form has high purity, the preparation method is mild, the operation is simple, the introduction of impurities is small, and the weight is small. The present is good, the production process is easy to control, and the safety is high, which is suitable for industrial production.
  • Figure 1 is a powder diffraction pattern of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I;
  • Figure 2 is a crystal structure diagram of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I;
  • FIG. 3 is a differential scanning calorimetry (DSC) chart of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I;
  • FIG. 4 is an infrared spectrum (IR) image of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I;
  • FIG. 5 is a thermogravimetric analysis (TG) diagram of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I.
  • terapéuticaally effective amount means an amount sufficient to effect treatment when administered to a patient in need of treatment.
  • treating means treating a disease, disorder or medical condition of a patient, such as a mammal, especially a human, comprising:
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidinoacetamide colorless sand granular crystal obtained in Example 1 was subjected to crystal parameter measurement, including powder diffraction measurement, infrared spectrum measurement, differential calorimetry, and Thermogravimetric analysis.
  • Test instrument conditions The test used DX2500 X-ray diffractometer (Liaoning Dleveragingyuan Instrument) to analyze the pre-oxidized and carbonized particles at various stages of the thermal stabilization process.
  • the crystals prepared in Example 1 had diffraction at diffraction angles 2 ⁇ of 12.423, 14.928, 16.285, 16.465, 17.344, 19.198, 20.459, 20.707, 21.548, 21.889, 23.203, 25.054, 26.117, 29.913, 30.49, 35.138, 37.569, 37.972°.
  • the peak, powder diffraction results are shown in Figure 1.
  • the crystal form is defined as (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I.
  • the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has a powder X-ray pattern expressed by a crystal plane spacing d, a Bragg angle (2 ⁇ ), and a relative intensity percentage I crystal form. ,As follows:
  • DSC Differential Scanning Thermal Analysis
  • DSC test uses NETZSCH DSC200PC type tester. The test method is to accurately weigh a certain amount (1 ⁇ 2mg) of the sample in DSC ⁇ , after sealing and sealing, take empty space as reference, from 20°C The temperature was raised to 200 ° C, the heating rate was 3 ° C / min, and the nitrogen flow rate in the sample chamber was 20 mL / min.
  • the differential scanning thermal analysis (DSC) chart of the crystal form I of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide of the present invention is shown in Fig. 3, and the endothermic transition temperature is about 133.1 ⁇ 2 °C. .
  • Test equipment and conditions using NICOLET 6700U.SA Fourier transform infrared spectrometer, the measurement method is GB/T 6040-2002 infrared spectrum analysis method, sample processing using solid potassium bromide tablet (24 ° C, 60%), determination Its infrared spectrum.
  • the infrared spectrum of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I is shown in Fig.
  • the wave number is 3413 (cm -1 ), 3353 (cm -1 ), 3182 ( Cm -1 ), 2961 (cm -1 ), 2880 (cm -1 ), 2797 (cm -1 ), 1671 (cm -1 ), 1491 (cm -1 ), 1452 (cm -1 ), 1398 (cm -1 ), 1308 (cm -1 ), 1240 (cm -1 ), 1199 (cm -1 ), 1081 (cm -1 ), 1037 (cm -1 ), 1012 (cm -1 ), 947 (cm - 1 ), 671 (cm -1 ), 613 (cm -1 ), and 462 (cm -1 ) have absorption peaks.
  • Test equipment and conditions Tested by Shimadzu DTG-60, the test method is to accurately weigh a certain amount ( ⁇ 5mg) of the sample in aluminum crucible, the heating rate is 10 °C / min for testing, nitrogen flow rate 50mL / min, from room temperature The temperature was raised to 600 ° C at (20 ° C), and the DTA-TGA curve was measured using ⁇ -Al 2 O 3 as a reference.
  • the results of the thermogravimetric analysis (TG) of the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention are shown in Fig. 5.
  • Example 1 0.23% 0.35% 0.12%
  • Example 3 0.22% 0.36% 0.14%
  • Example 4 0.26% 0.39% 0.13%
  • Example 5 0.25% 0.37% 0.12%
  • Example 6 0.26% 0.37% 0.11%
  • Example 7 0.22% 0.33% 0.11%
  • the related substance of the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention is not changed much at a high temperature of 60 ° C, and the change of the related substance in 5 days is less than 0.15%. Therefore, the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention has good stability against high temperature.
  • the angle of repose is the easiest way to check the fluidity of the powder. The smaller the angle of repose, the smaller the friction and the better the fluidity.
  • the angle of repose of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide Form I prepared by the methods of Examples 1 and 3-7 was measured by an injection method (fixed funnel method). Pour the sample to be tested into the funnel, and gently and evenly fall into the center of the disc to form a cone. When the material falls freely from the oblique edge of the powder along the edge of the disc, the feeding is stopped, and the angle of repose is measured by a protractor; The sample traits and the clarity of the solution were examined. Each group was tested for 5 groups and the average was obtained. The results are as follows:
  • Example 1 White crystalline powder clarify 28.0
  • Example 3 White crystalline powder clarify 28.3
  • Example 4 White crystalline powder clarify 28.5
  • Example 5 White crystalline powder clarify 27.8
  • Example 6 White crystalline powder clarify 27.8
  • Example 7 White crystalline powder clarify 28.0
  • Examples 1, 3-7 that is, the (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I of the present invention, the particles thereof The angle of repose is less than 30 degrees, indicating good fluidity, which can meet the liquidity requirement in the production process, and is suitable for the production of pharmaceutical preparations, storage and transportation; therefore, (R)-4-hydroxy-2-oxo-1 according to the present invention - Pyrrolidin acetamide crystal form I has better particle flowability and better meets production requirements than the prior art.
  • (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form 200 mg/granule prepared according to Example 1, lactose 80.8 mg/granule, sodium carboxymethyl starch 72 mg/granule, talc powder 7.2 mg/ Granules and 10% polyvinylpyrrolidone in an appropriate amount; taking 1000 tablets of (R)-4-hydroxy-2-oxo-1-pyrrolidinoacetamide crystal form I capsule as an example, the specific preparation method is: firstly the original auxiliary materials 80 mesh sieve, weigh the above amount of (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide crystal form I, lactose, sodium carboxymethyl starch, evenly mixed, add 10% PVP ethanol solution to make soft materials , granulating, drying, granulating, adding the above amount of talc powder to the granules, mixing evenly, filling the capsules.
  • (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form 200 mg/tablet, starch 34 mg/tablet, microcrystalline cellulose 60 mg/tablet, talc 6 mg/tablet and 2 prepared according to Example 1.
  • % hydroxypropyl methylcellulose K4M model
  • the specific preparation method is: First, the original auxiliary material is passed through an 80 mesh sieve, and the above amount of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I, starch, and microcrystalline cellulose are uniformly mixed, and an appropriate amount of 2% HPMC is added.
  • the aqueous solution is made of soft material, granulated, dried, and granulated.
  • the prescribed amount of talc powder is added to the granules, uniformly mixed, and tableted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

本发明提供一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型，在2θ为12.423±0.2°、16.465±0.2°、17.344±0.2°、21.889±0.2°、25.054±0.2°处有衍射峰。本发明能促进磷酰胆碱和邻酰乙醇胺合成，促进脑代谢，通过血脑屏障对特异性中枢神经通路有刺激作用，在镇静，抗癫痫等领域有特殊的生物学活性。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型的熔点峰值温度为133.1±2℃，在水中溶解速度快，水中溶解度≥100mg/mL，生物利用度高，稳定性好，颗粒流动性好，适合应用于生产药物制剂及储藏运输；适合制成多种药物组合物，可制成多种制剂如片剂、胶囊剂、滴丸剂、缓释控释制剂、冻干粉针剂等。本发明制备方法简单，适合工业化生产。

Description

(R)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途
相关申请的交叉引用
本申请要求2017年1月12日提交的中国专利申请201710021990.0的优先权，所述申请的公开内容均援引加入本文。
技术领域
本发明涉及(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，具体涉及一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型、制备方法和用途。
背景技术
(R)-4-羟基-2-氧-1-吡咯烷乙酰胺(CAS号为68252-28-8)，是促智药4-羟基-2-氧-1-吡咯烷乙酰胺的右旋体。最新研究表明，该化合物在镇静、抗癫痫等领域有特殊的生物学活性，并且其毒性低，药物安全范围大，有望成为现有的高毒性抗癫痫类药物的替代品。(R)-4-羟基-2-氧-1-吡咯烷乙酰胺具体结构如下：
Figure PCTCN2017118180-appb-000001
(R)-4-羟基-2-氧-1-吡咯烷乙酰胺
为有效将(R)-4-羟基-2-氧-1-吡咯烷乙酰胺开发成药品，需要一种具有易于制造并且可接受的化学和物理稳定性的固态形式，以促进其加工与流通储存。对于增强化合物的纯度和稳定性而言，结晶固体形态一般优于非晶型形态。目前(R)-4-羟基-2-氧-1-吡咯烷乙酰胺的制备方法及晶型研究较少，尚未有(R)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型披露。
发明内容
为了解决现有技术中的问题，根据本发明的第一方面，本发明的目的在于提供一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型。本发明的完整特性如下文所述，但是为了方便起见，将所提供的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型称为“(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I”。
除特殊说明外，本发明所述份数均为重量份，所述百分比均为质量百分比。
本发明的目的是这样实现的：
一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、16.465±0.2°、17.344±0.2°、21.889±0.2°、25.054±0.2°处有衍射峰。
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在衍射角度2θ为17.344±0.2°处的相对峰强度为100％；在衍射角度2θ为16.465±0.2°的相对峰强度大于90％小于100％；在衍射角度2θ为12.423±0.2°、21.889±0.2°、25.054±0.2°的相对峰强度不小于70％。
进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、20.707±0.2°、21.889±0.2°、25.054±0.2°、35.138±0.2°处有衍射峰。
更进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、14.928±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、19.198±0.2°、20.459±0.2°、20.707±0.2°、21.548±0.2°、21.889±0.2°、23.203±0.2°、25.054±0.2°、26.117±0.2°、29.913±0.2°、30.49±0.2°、35.138±0.2°、37.569±0.2°、37.972±0.2°处有衍射峰。具体的，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I具有如图1所示的粉末衍射图谱。
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，具有下列d
Figure PCTCN2017118180-appb-000002
值和相对强度百分比I(％)值表达的-X射线粉末衍射数据，
Figure PCTCN2017118180-appb-000003
Figure PCTCN2017118180-appb-000004
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的晶胞为Orthorhombic(正交晶系)，
Figure PCTCN2017118180-appb-000005
具体的，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I具有如图2所述的晶体结构图。
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的熔点峰值温度为133.1±2℃。具体的，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I具有如图3所示的差示扫描热分析(DSC)图谱。
进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在衍射角度2θ为12.423±0.2°、14.928±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、19.198±0.2°、20.459±0.2°、20.707±0.2°、21.548±0.2°、21.889±0.2°、23.203±0.2°、25.054±0.2°、26.117±0.2°、29.913±0.2°、30.49±0.2°、35.138±0.2°、37.569±0.2°、37.972±0.2°处有衍射峰；吸热转变温度为133.1±2℃。
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I产生的红外光谱在以下波数显示出吸收峰：
3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)， 1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)，613(cm -1)，462(cm -1)。具体的，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I具有如图4所述的红外光谱图。
进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在衍射角度2θ为12.423±0.2°、14.928±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、19.198±0.2°、20.459±0.2°、20.707±0.2°、21.548±0.2°、21.889±0.2°、23.203±0.2°、25.054±0.2°、26.117±0.2°、29.913±0.2°、30.49±0.2°、35.138±0.2°、37.569±0.2°、37.972±0.2°处有衍射峰；在以下波数显示出红外吸收峰：
3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)，1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)，613(cm -1)，462(cm -1)。
进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I产生的红外光谱在以下波数显示出吸收峰：
3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)，1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)，613(cm -1)，462(cm -1)；吸热转变温度为133.1±2℃。
更进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在衍射角度2θ为12.423±0.2°、14.928±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、19.198±0.2°、20.459±0.2°、20.707±0.2°、21.548±0.2°、21.889±0.2°、23.203±0.2°、25.054±0.2°、26.117±0.2°、29.913±0.2°、30.49±0.2°、35.138±0.2°、37.569±0.2°、37.972±0.2°处有衍射峰；晶胞为Orthorhombic(正交晶系)，
Figure PCTCN2017118180-appb-000006
吸热转变温度为133.1±2℃；在以下波数显示出红外吸收峰：
3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)，1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)，613(cm -1)，462(cm -1)。
根据本发明的第二方面，本发明的目的在于提供一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备方法。
一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备方法，采用如下步骤：
(1)、在异丙醇或仲丁醇中加入(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至30℃～100℃，过滤，形成过饱和溶液；
(2)、将步骤(1)得到的过饱和溶液密封放置在-10℃～-19℃的低温环境中冷却结晶，得到(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
进一步，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备方法，采用以下步骤：
(1)、在异丙醇或仲丁醇中以5mg/mL-50mg/mL加入(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至40℃～50℃，过滤，形成过饱和溶液；
(2)、将步骤(1)得到的过饱和溶液密封放置在-15℃～-19℃的低温环境中冷却结晶，得到(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
根据本发明第三方面，本发明提供(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫药物中的应用。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫急性发作药物中的应用，尤其是在制备抗癫痫急性大发作药物中的应用。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫全身性发作药物中的应用。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫部分性发作药物中的应用。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫持续状态药物中的应用。本发明所述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在稳定大脑异常放电，镇静，抗癫痫等方面有特殊的药理学活性，而其在水中溶解度≥100mg/mL，生物利用度高。
根据本发明的第四方面，本发明提供一种药物组合物，包含上述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I和在药学上可接受的辅料。本发明药物组合物包含治疗有效量(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I和在药学上可接受的辅料；可通过任何可接受的投药途径向患者投与所述药物组合物，可接受的投药途径包括(但不限于)经口、经直肠、经阴道、经鼻、吸入、局部(包括经皮)和不经肠投药方式，包括片剂、散剂、颗粒剂、注射剂、胶囊剂、滴丸剂、缓释控释制剂、冻干粉针剂。
有益效果：
本发明提供一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型，在2θ为12.423±0.2°、16.465±0.2°、17.344±0.2°、21.889±0.2°、25.054±0.2°处有衍射 峰，其中在衍射角度2θ为17.344±0.2°处的相对峰强度为100％。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型能促进磷酰胆碱和邻酰乙醇胺合成，促进脑代谢，通过血脑屏障对特异性中枢神经通路有刺激作用，在镇静、抗癫痫等领域有特殊的生物学活性。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I对癫痫急性发作作用明显，尤其是癫痫急性大发作有明显的抑制作用；本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I对癫痫全身性发作、癫痫部分性发作以及癫痫持续状态均有较好的抑制作用，而且本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I生物利用度高，毒性低，适合开发成为抗癫痫药物。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型的熔点峰值温度为133.1±2℃，在水中溶解速度快，水中溶解度≥100mg/mL，生物利用度高。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型在60℃高温条件放置5天有关物质变化小，对高温的稳定性很好，同时本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型颗粒流动性良好，可满足生产过程中的流动性需求，适合应用于生产药物制剂及储藏运输；适合制成多种药物组合物，可制成多种制剂如片剂、胶囊剂、滴丸剂、缓释控释制剂、冻干粉针剂等。本发明制备方法采用原料价廉易得，制得的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型纯度高，制备方法条件温和，操作简便，引入杂质少，重现性好，生产过程易于控制，安全性高，适合工业化生产。
附图说明
图1是(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的粉末衍射图；
图2是(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的晶体结构图；
图3是(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的差示扫描热分析(DSC)图；
图4是(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的红外光谱(IR)图；
图5是(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的热重分析(TG)图。
定义
当描述本发明的化合物、组合物和方法时，除非另作说明，否则以下术语具有以下含义。
术语“治疗有效量”意指当投与需要治疗的患者时足以实现治疗的量。如本文中所用的术语“治疗”意指治疗例如哺乳动物(尤其人类)的患者的疾病、病症或医学病况，其包括：
(a)预防疾病、病症或医学病况发生，即对患者的预防性治疗；
(b)改善疾病、病症或医学病况，即消除患者的疾病、病症或医学病 况或使其消退，包括抵消其它治疗剂的效果。
(c)抑制疾病、病症或医学病况，即减缓或遏止患者的疾病、病症或医学病况的发展；或
(d)减轻患者的疾病、病症或医学病况的症状。
须注意除非内容另外明确规定，否则如本说明书和随附权利要求书中所用，单数形式“一”和“所述”可包括复数个提及物。
具体实施方式
下面通过具体实施例对本发明进行具体描述，在此指出以下实施例只用于对本发明进行进一步说明，不能理解为对本发明保护范围的限制，本领域的技术熟练人员可以根据上述发明内容对本发明作出一些非本质的改进和调整。本发明所有原料及试剂均为市售产品，其中(R)-4-羟基-2-氧-1-吡咯烷乙酰胺由重庆东泽医药科技发展有限公司提供。本发明搅拌、加热、过滤等概念是本领域技术人员明确知晓，按照本领域常规操作进行。
(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备
实施例1
在2mL仲丁醇中加入50mg(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至40℃，过滤，得过饱和溶液，将此溶液密封放置在-19℃环境下冷却析晶24小时，得到无色砂粒状晶体。
实施例2
将实施例1得到的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺无色砂粒状晶体进行晶体参数测定，包括粉末衍射测定、红外光谱测定、差示热量扫描法测定、热重分析测定。测试仪器条件：测试采用DX2500型X射线衍射仪(辽宁丹东方圆仪器)分析热稳定化过程中各阶段的预氧体和碳化制得的微粒。Ni滤波，CuKα为辐射源，X射线波长λ＝0.1541nm，加速电压和电流强度分别为40kV和50mA。设定扫描间隔为0.02°，扫描速度为3°/min，扫描范围为5～45°。实施例1制备的晶体在衍射角度2θ为12.423、14.928、16.285、16.465、17.344、19.198、20.459、20.707、21.548、21.889、23.203、25.054、26.117、29.913、30.49、35.138、37.569、37.972°处有衍射峰，粉末衍射结果如图1所示，为方便起见，将该晶型定义为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
本发明的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其粉末X射线图以晶面间距d、Bragg角(2θ)和相对强度的百分比I晶型表达，如下所示：
Figure PCTCN2017118180-appb-000007
晶体结构图测定：
对(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的单晶结构进行了解析，其晶胞为Orthorhombic晶系，空间群为
Figure PCTCN2017118180-appb-000008
α＝90.00 o，β＝90.00 o，γ＝90.00 o，晶胞体积
Figure PCTCN2017118180-appb-000009
其晶体结构如图2所示。
本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的晶体学参数如下表所示：
Figure PCTCN2017118180-appb-000010
差示扫描热分析(DSC)图测定：
测试仪器及条件：DSC测试采用NETZSCH DSC200PC型测试仪，测试方法为准确称取一定量(1～2mg)的样品于DSC坩埚中，坩埚加盖密封后，以空坩埚作为参比，从20℃加热至200℃，升温速率为3℃/min，样品室氮气流量为20mL/min。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的差示扫描热分析(DSC)图如图3所示，其吸热转变温度在133.1±2℃左右。
红外光谱(IR)图测定：
测试仪器及条件：采用NICOLET 6700U.S.A傅里叶变换红外光谱仪，测定方式采用GB/T 6040-2002红外光谱分析方法通则，样品处理采用固体溴化钾压片(24℃,60％)，测定其红外光谱图谱。(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的红外光谱图如图4所示，在波数为3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)，1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)，613(cm -1)，462(cm -1)处有吸收峰。
热重分析(TG)测定：
测试仪器及条件：采用岛津DTG-60进行测试，测试方法为准确称取一定量(＜5mg)样品于铝制坩埚中，升温速率10℃/min进行测试，氮气 流量50mL/min，从室温(20℃)升温至600℃，以α-Al2O3作为参比，测定DTA-TGA曲线。本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I热重分析(TG)测定结果见图5。
实施例3
在2mL异丙醇中，加入20mg(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至50℃，过滤，得过饱和溶液，将此溶液密封放置在-17℃环境下冷却析晶3小时，得到无色沙粒状晶体。用实施例2的方法鉴定，为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
实施例4
在30mL仲丁醇中，加入1g(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至45℃，过滤，得过饱和溶液，将此溶液密封放置在-18℃环境下冷却析晶36小时，得到无色沙粒状晶体。用实施例2的方法鉴定，为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
实施例5
在10mL异丙醇中，加入50mg(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至30℃，过滤，得过饱和溶液，将此溶液密封放置在-10℃环境下24小时冷却析晶，得到无色沙粒状晶体。用实施例2的方法鉴定，为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
实施例6
将60mg(R)-4-羟基-2-氧-1-吡咯烷乙酰胺溶解在2mL仲丁醇溶液中，加热50℃溶解，过滤，得过饱和溶液，将此溶液密封放置在-19℃环境下冷却析晶36小时，得到无色沙粒状晶体，用实施例2的方法鉴定，为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
实施例7
在2mL异丙醇中加入(R)-4-羟基-2-氧-1-吡咯烷乙酰胺100mg，不断搅拌，100℃加热溶解，过滤，得过饱和溶液，将此溶液密封放置在-18℃环境下冷却析晶36小时，得到无色沙粒状晶体。用实施例2的方法鉴定，为(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
实施例8
(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在高温条件下的稳定性试验。取实施例1、3-7制得的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I置扁形称量瓶中，摊成≤5mm厚的薄层，分别置密封洁净容器中，在60℃条件下放置5 天；分别于第0天和第5天取样，检测。每个实施例检测5组，取平均数，结果如下表：
在60℃高温条件放置变化情况
0天：有关物质 5天：有关物质 有关物质变化
实施例1 0.23％ 0.35％ 0.12％
实施例3 0.22％ 0.36％ 0.14％
实施例4 0.26％ 0.39％ 0.13％
实施例5 0.25％ 0.37％ 0.12％
实施例6 0.26％ 0.37％ 0.11％
实施例7 0.22％ 0.33％ 0.11％
由上表可见，本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在60℃高温条件放置的有关物质变化不大，5天有关物质变化小于0.15％。因而本发明(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I对高温的稳定性好。
实施例9
休止角是检验粉体流动性好坏的最简便的方法，休止角越小，说明摩擦力越小，流动性越好。本试验采用注入法(固定漏斗法)测定实施例1、3-7方法制备的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的休止角。将待测样品倒入漏斗，使其轻轻地、均匀地落入圆盘中心，形成一个圆锥体，当物料从粉体斜边沿圆盘边缘中自由落下时停止加料，用量角器测定休止角；并考察样品性状和溶液澄清度，每个实施例检测5组，取平均数，结果如下表：
样品性状、休止角、溶液澄清度等测定结果
样品性状 溶液澄清度 休止角
实施例1 白色结晶性粉末 澄清 28.0
实施例3 白色结晶性粉末 澄清 28.3
实施例4 白色结晶性粉末 澄清 28.5
实施例5 白色结晶性粉末 澄清 27.8
实施例6 白色结晶性粉末 澄清 27.8
实施例7 白色结晶性粉末 澄清 28.0
由上表的试验结果可看出：实施例1、3-7，也即本发明所述的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其颗粒的休止角小于30度，表明流动性良好， 可满足生产过程中的流动性需求，适合应用于生产药物制剂及储藏运输；故本发明所述的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I与现有技术相比，其颗粒流动性更好，更能满足生产需求。
(三)含(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I组合物的制备
实施例10
按照实施例1制备的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型200mg/粒、乳糖80.8mg/粒、羧甲基淀粉钠72mg/粒、滑石粉7.2mg/粒和10％聚乙烯吡咯烷酮适量；以制成1000粒(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I胶囊剂为例，具体制备方法是：先将原辅料过80目筛，称取上述量的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I、乳糖、羧甲基淀粉钠混合均匀，加10％PVP乙醇溶液制软材，制粒，烘干，整粒，向颗粒中加入上述量的滑石粉，混合均匀，充填胶囊。
实施例11
按照实施例1制备的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型200mg/片、淀粉34mg/片、微晶纤维素60mg/片、滑石粉6mg/片和2％羟丙基甲基纤维素(K4M型号)适量；以制成1000片(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I片剂为例，具体制备方法是：先将原辅料过80目筛，称取上述量的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I、淀粉、微晶纤维素混合均匀，加适量2％HPMC水溶液制软材，制粒，烘干，整粒，向颗粒中加入处方量的滑石粉，混合均匀，压片。
实施例12
按照实施例1制得的I晶型(R)-4-羟基-2-氧-1-吡咯烷乙酰胺50g，葡萄糖150g，500ml注射用水溶解于稀配罐中，温度控制在50～60℃，搅拌直至完全溶解，将溶解液冷却到25℃，向上述配好的溶解液中加入活性炭脱色，再将其中的活性炭过滤除去，加入磷酸盐缓冲液将该溶解液的pH值调节为4.0，再加入注射用水至5000ml，灌封，在105℃灭菌30分钟，得到注射液。

Claims (16)

  1. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、16.465±0.2°、17.344±0.2°、21.889±0.2°、25.054±0.2°处有衍射峰。
  2. 如权利要求1所述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：在衍射角度2θ为17.344±0.2°处的相对峰强度为100％；在衍射角度2θ为16.465±0.2°的相对峰强度大于90％小于100％；在衍射角度2θ为12.423±0.2°、21.889±0.2°、25.054±0.2°的相对峰强度不小于70％。
  3. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、20.707±0.2°、21.889±0.2°、25.054±0.2°、35.138±0.2°处有衍射峰。
  4. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，在衍射角度2θ为12.423±0.2°、14.928±0.2°、16.285±0.2°、16.465±0.2°、17.344±0.2°、19.198±0.2°、20.459±0.2°、20.707±0.2°、21.548±0.2°、21.889±0.2°、23.203±0.2°、25.054±0.2°、26.117±0.2°、29.913±0.2°、30.49±0.2°、35.138±0.2°、37.569±0.2°、37.972±0.2°处有衍射峰。
  5. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，具有如图1所示的粉末衍射图谱。
  6. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，具有下列
    Figure PCTCN2017118180-appb-100001
    值和相对强度百分比I(％)值表达的X-射线粉末衍射数据，
    Figure PCTCN2017118180-appb-100002
    Figure PCTCN2017118180-appb-100003
  7. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：所述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的晶胞为Orthorhombic(正交晶系)，
    Figure PCTCN2017118180-appb-100004
  8. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：具有如图2所述的晶体结构图。
  9. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：所述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的熔点峰值温度为133.1±2℃。
  10. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：具有如图3所示的差示扫描热分析(DSC)图谱。
  11. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：所述(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I产生的红外光谱在以下波数显示出吸收峰：
    3413(cm -1)，3353(cm -1)，3182(cm -1)，2961(cm -1)，2880(cm -1)，2797(cm -1)，1671(cm -1)，1491(cm -1)，1452(cm -1)，1398(cm -1)，1308(cm -1)，1240(cm -1)，1199(cm -1)，1081(cm -1)，1037(cm -1)，1012(cm -1)，947(cm -1)，671(cm -1)， 613(cm -1)，462(cm -1)。
  12. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I，其特征在于：具有如图4所示的红外光谱图谱。
  13. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备方法，采用如下步骤：
    (1)、在异丙醇或仲丁醇中加入(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至30℃～100℃，过滤，形成过饱和溶液；
    (2)、将步骤(1)得到的过饱和溶液密封放置在-10℃～-19℃的低温环境中冷却结晶，得到(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
  14. 一种(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的制备方法，采用以下步骤：
    (1)、在异丙醇或仲丁醇中以5mg/mL-50mg/mL加入(R)-4-羟基-2-氧-1-吡咯烷乙酰胺，不断搅拌，加热至40℃～50℃，过滤，形成过饱和溶液；
    (2)、将步骤(1)得到的过饱和溶液密封放置在-15℃～-19℃的低温环境中冷却结晶，得到(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I。
  15. (R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I在制备抗癫痫药物中的应用。
  16. 一种包含医药上可接受的载剂或赋形剂和治疗有效量的(R)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型I的医药组合物。
PCT/CN2017/118180 2017-01-12 2017-12-25 (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 WO2018130063A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020197019929A KR20190095346A (ko) 2017-01-12 2017-12-25 (r)-4-하이드록시-2-옥소-피롤리딘아세트아미드 결정형, 이의 제조 방법 및 용도
US16/476,477 US10961192B2 (en) 2017-01-12 2017-12-25 (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof
EP17891064.2A EP3569590A4 (en) 2017-01-12 2017-12-25 CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINEACETAMIDE, ITS PREPARATION METHOD AND ITS APPLICATION
JP2019535846A JP2020504124A (ja) 2017-01-12 2017-12-25 （ｒ）−４−ヒドロキシ−２−オキソ−１−ピロリジンアセトアミドの結晶形、その調製方法および使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710021990.0 2017-01-12
CN201710021990.0A CN108299267A (zh) 2017-01-12 2017-01-12 (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2018130063A1 true WO2018130063A1 (zh) 2018-07-19

Family

ID=62840199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/118180 WO2018130063A1 (zh) 2017-01-12 2017-12-25 (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途

Country Status (6)

Country Link
US (1) US10961192B2 (zh)
EP (1) EP3569590A4 (zh)
JP (1) JP2020504124A (zh)
KR (1) KR20190095346A (zh)
CN (1) CN108299267A (zh)
WO (1) WO2018130063A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556863B1 (en) 2016-10-24 2020-02-11 Chongqing Ruzer Pharmaceutical Company Limited Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof
US10696629B2 (en) 2016-10-24 2020-06-30 Chongqing Runze Pharmaceutical Company Limited Crystalline form of dextral oxiracetam, preparation method therefor and use thereof
US10793521B2 (en) 2016-10-24 2020-10-06 Chongqing Ruzer Pharmaceutical Company Limited Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof
US10961192B2 (en) 2017-01-12 2021-03-30 Chongqing Ruzer Pharmaceutical Company Limited (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124594A (en) * 1977-02-11 1978-11-07 I.S.F. Spa 4-Hydroxy pyrrolidin-2-onyl-amides
CN102603607A (zh) * 2011-01-21 2012-07-25 重庆润泽医疗器械有限公司 （r）-奥拉西坦的制备方法
CN103553998A (zh) * 2013-11-06 2014-02-05 重庆润泽医药有限公司 （s）-奥拉西坦晶型iii的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075280B (it) 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
KR100679633B1 (ko) 2004-07-27 2007-02-07 한국화학연구원 광학 활성을 갖는 옥시라세탐의 제조 방법
CN102442936A (zh) 2010-10-09 2012-05-09 重庆润泽医疗器械有限公司 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺的纯化方法
CN102249977B (zh) 2011-08-11 2013-06-12 重庆润泽医药有限公司 4-羟基-2-氧代-1-吡咯烷乙酰胺外消旋体晶型ⅰ及其制备方法
CN102558014B (zh) * 2011-11-09 2013-11-06 天津市汉康医药生物技术有限公司 稳定晶型的奥拉西坦化合物
CN102600130A (zh) 2012-03-26 2012-07-25 北京阜康仁生物制药科技有限公司 奥拉西坦及其光学异构体的新临床用途
CN103342673B (zh) * 2013-07-31 2015-11-18 石药集团欧意药业有限公司 一种奥拉西坦晶型及其制备方法
CN103554000B (zh) * 2013-11-06 2015-03-11 重庆润泽医药有限公司 (s)-奥拉西坦晶型iii及其制备方法和用途
CN108467355A (zh) 2014-08-07 2018-08-31 重庆润泽医药有限公司 (r)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法
CN105820101B (zh) * 2015-01-04 2018-12-18 哈尔滨三联药业股份有限公司 一种旋光纯1-(氨基甲酰基)甲基-4-羟基-2-吡咯烷酮的制备方法
JP6527290B2 (ja) * 2015-05-18 2019-06-05 重慶潤澤医薬有限公司 製薬領域における右旋性オキシラセタムの応用
EP3530271A4 (en) 2016-10-24 2020-03-25 Chongqing Runze Pharmaceutical Company Limited CRYSTALLINE FORM II OF DEXTRAL-OXIRACETAM, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
US10556863B1 (en) * 2016-10-24 2020-02-11 Chongqing Ruzer Pharmaceutical Company Limited Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof
WO2018076782A1 (zh) 2016-10-24 2018-05-03 重庆润泽医药有限公司 右旋奥拉西坦新晶型及其制备方法和用途
CN108299267A (zh) 2017-01-12 2018-07-20 重庆润泽医药有限公司 (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124594A (en) * 1977-02-11 1978-11-07 I.S.F. Spa 4-Hydroxy pyrrolidin-2-onyl-amides
CN102603607A (zh) * 2011-01-21 2012-07-25 重庆润泽医疗器械有限公司 （r）-奥拉西坦的制备方法
CN103553998A (zh) * 2013-11-06 2014-02-05 重庆润泽医药有限公司 （s）-奥拉西坦晶型iii的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 68252-28-8
MIYAMOTO, SHIGETOSHI: "Synthesis of 4-Hydroxy-2-pyrrolidinone Derivatives", NEUROSCIENCES, vol. 11, no. 1, 1 January 1985 (1985-01-01), pages 1 - 8, XP000671513, ISSN: 0388-7448 *
See also references of EP3569590A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556863B1 (en) 2016-10-24 2020-02-11 Chongqing Ruzer Pharmaceutical Company Limited Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof
US10696629B2 (en) 2016-10-24 2020-06-30 Chongqing Runze Pharmaceutical Company Limited Crystalline form of dextral oxiracetam, preparation method therefor and use thereof
US10793521B2 (en) 2016-10-24 2020-10-06 Chongqing Ruzer Pharmaceutical Company Limited Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof
US10961192B2 (en) 2017-01-12 2021-03-30 Chongqing Ruzer Pharmaceutical Company Limited (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof

Also Published As

Publication number Publication date
US10961192B2 (en) 2021-03-30
KR20190095346A (ko) 2019-08-14
US20190367454A1 (en) 2019-12-05
EP3569590A4 (en) 2020-07-08
EP3569590A1 (en) 2019-11-20
CN108299267A (zh) 2018-07-20
JP2020504124A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
WO2018130063A1 (zh) (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
US20230183172A1 (en) Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
KR20190020753A (ko) 트리아졸로피리미딘 화합물의 결정질 형태
ES2971478T3 (es) Formas en estado sólido de sofosbuvir
CN107973737B (zh) 右旋奥拉西坦新晶型及其制备方法和用途
WO2018076784A1 (zh) （r）-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型及其制备方法和用途
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
WO2018076783A1 (zh) 右旋奥拉西坦晶型ii及其制备方法和用途
TWI745289B (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
WO2015067130A1 (zh) (s)-奥拉西坦晶型iii及其制备方法和用途
CN114948868B (zh) 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN102351881B (zh) 一种稳定的盐酸左氧氟沙星化合物
CN106478616B (zh) 一种gpr40激动剂的结晶形式及其制备方法
ES2717254T3 (es) Formas en estado sólido de sofosbuvir
WO2018130062A1 (zh) 一种(r)-4-羟基-2-氧-1-吡咯烷乙酰胺晶型的制备方法
WO2019233328A1 (zh) 4-苯基噻唑衍生物的晶型及其制备方法
CN107973740A (zh) 一种右旋奥拉西坦化合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17891064

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019535846

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197019929

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017891064

Country of ref document: EP

Effective date: 20190812